Biovail Puts Up $37.5M To Ditch Wellbutrin Antitrust Case
Biovail Corp., now part of Valeant Pharmaceuticals International Inc., agreed to pay $37.5 million Monday to settle direct purchasers' claims in antitrust multidistrict litigation alleging it conspired to stifle the market...To view the full article, register now.
Already a subscriber? Click here to view full article